Nicole Parrish
Johns Hopkins University School of Medicine
71 Papers
248 Citations
Nicole Parrish is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Medicine & Mycobacterium tuberculosis. The author has an hindex of 19, co-authored 67 publications. Previous affiliations of Nicole Parrish include Johns Hopkins University & University Health System.
Chat about Author
Papers
Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection.
Rebekah M. Dedrick,Krista G. Freeman,Jan A. Nguyen,Asli Bahadirli-Talbott,Bailey E. Smith,Andrew E. Wu,Aaron S. Ong,Cheng Ting Lin,Lisa C. Ruppel,Nicole Parrish,Graham F. Hatfull,Keira A. Cohen +11 more
TL;DR: In this article, an 81-year-old immunocompetent patient with bronchiectasis and refractory Mycobacterium abscessus lung disease was treated for 6 months with a three-phage cocktail active against the strain.
130
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus
TL;DR: The combination of faropenem and rifampin and (carba)penems were effective not only against drug-sensitive Mycobacterium tuberculosis but alsoagainst drug-resistant clinical isolates that are otherwise resistant to rifampsin.
119
The Consensus from the Mycobacterium avium ssp. paratuberculosis (MAP) Conference 2017
J. Todd Kuenstner,Saleh A. Naser,William Chamberlin,Thomas J. Borody,David Y. Graham,Adrienne McNees,John Hermon-Taylor,Amy Hermon-Taylor,C. Thomas Dow,Walter Thayer,James Biesecker,Michael T. Collins,Leonardo A. Sechi,Shoor Vir Singh,Peilin Zhang,Ira Shafran,Stuart Weg,Grzegorz Telega,Robert Rothstein,Harry Oken,Stephen Schimpff,Horacio Bach,Tim J. Bull,Irene R. Grant,Jay L. E. Ellingson,Heinrich Dahmen,Judith Lipton,Saurabh Gupta,Kundan Kumar Chaubey,Manju Singh,Prabhat Agarwal,Ashok Kumar,Jyoti Misri,Jagdip Singh Sohal,Kuldeep Dhama,Zahra Hemati,William Davis,Michael Hier,John Aitken,Ellen Pierce,Nicole Parrish,Neil D. Goldberg,Maher Kali,Sachin Bendre,Gaurav Agrawal,Robert N. Baldassano,Preston Linn,Raymond W. Sweeney,Marie Fecteau,Casey E. Hofstaedter,Raghava Potula,Olga A. Timofeeva,Steven Geier,Kuruvilla John,Najah Zayanni,Hoda M. Malaty,Christopher Kahlenborn,Amanda Kravitz,Adriano Bulfon,George Daskalopoulos,Hazel M. Mitchell,Brett A. Neilan,Verlaine J. Timms,Davide Cossu,Giuseppe Mameli,Paul Angermeier,Tomislav Jelic,Ralph Goethe,Ramon A. Juste,Lauren Kuenstner +69 more
TL;DR: On March 24 and 25, 2017 researchers and clinicians from around the world met at Temple University in Philadelphia to discuss the current knowledge of Mycobacterium avium ssp.
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.
TL;DR: In vitro activity of two newly approved tetracycline analogs, omadacyCline and eravacyclines, against 28 drug-resistant clinical isolates of M. abscessus complex is reported, indicating new treatment options for M.Abscessus infections.
92
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus.
Amit Kaushik,Chhavi Gupta,Stefanie L. Fisher,Elizabeth Story-Roller,Christos Galanis,Nicole Parrish,Gyanu Lamichhane +6 more
TL;DR: Avibactam restores MICs of tebipenems, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M.Abscessus infections.
64